Abbreviated Name

PaCa Bake Off 1

Lead Investigator

Haab, Brian — Van Andel Research Institute

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Lokshin, Anna — University of Pittsburgh Cancer Institute
• Batra, Surinder — University of Nebraska Medical Center
• Lampe, Paul — Fred Hutchinson Cancer Center
• Haab, Brian — Van Andel Research Institute
• Brand, Randall E. — University of Pittsburgh
• Hanash, Samir — The University of Texas MD Anderson Cancer Center
• Maitra, Anirban — NYU Langone Health
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

Specific Aim 1: Compare the performance of several candidate biomarkers for discriminating resectable PDAC from benign pancreatic disease both alone and in combination with CA19. Specific Aim 2: Test the value of novel combinations of biomarkers to identify candidates for further testing using the reference set.

Analytic Method

Once the composition of the sample set is finalized by the two CVCs, aliquots of the samples will be transferred to each of the four laboratories running the biomarker experiments. Each site will run its own biomarker assays and perform initial data processing. Based on rules that will be predetermined, each site will make classifications of each sample as a case or control. The calls and data will be sent to Dr. Huang at FHCRC. Dr. Huang will have access to the diagnoses associated with the samples, from which she will determine the performance of the candidate biomarkers and make statistical comparisons among them and CA19-9. CA19-9 measurements will be provided by the laboratories of Drs. Haab and Batra. Information on each of the candidate biomarkers is provided in the following sections.

Comments

No comments available.

Outcome

See manuscript

Secure Outcome

No secure outcome available.

Publications

• A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone.

Biomarkers

• APOA1
• CA19-9
• CA199:sTRA
• CEACAM5
• LRG1
• MUC4
• MUC5AC
• MUC5AC:sTRA
• THBS1
• TIMP1
• TIMP4

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

May 1 2017

Estimated Finish Date

Apr 30 2018

Finish Date

Nov 1 2024

Protocol ID

421

Protocol Type

Collaboration

Fields of Research

• Proteomics

Collaborative Group

G.I. and Other Associated Cancers Research Group

Cancer Types

• Malignant neoplasm of pancreas

Phased Status

1